Form IRANNOTICE NOVARTIS AG
Novartis AG
PO Box
CH 4002 Basel
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
February 1, 2023
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on February 1, 2023.
Respectfully submitted,
Novartis AG
/s/ KAREN L. HALE | /s/ HARRY KIRSCH |
Karen L. Hale | Harry Kirsch |
Chief Legal Officer | Chief Financial Officer |
of Novartis | of Novartis |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novartis (NVS) PT Raised to $116 at BMO Capital
- Ero Copper Announces Voting Results of Annual General Meeting of Shareholders
- Net Income of R$ 55.3 mm in 1Q24, a 90.1% Increase YOY and Leases EBITDA Margin of 72.1%
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!